GSK Finalizes Acquisition Of Nanjing Meirui For $70 Million
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - GlaxoSmithKline announced that the company has reached an agreement to acquire urology-dedicated Nanjing MeiRui in China for $70 million to expand its urology and over-the-counter presence in China's booming pharmaceutical market
You may also be interested in...
GSK Buys Out Neptunus Stake in Chinese Vaccines JV; Are New Pharmacopoeia Standards At Play?
In an effort to increase its footprint in the Chinese vaccine market, GlaxoSmithKline PLC will acquire the remaining 51% equity stake in its joint venture with China's Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. for $39 million in cash, the companies announced June 14
GSK Buys Out Neptunus Stake in Chinese Vaccines JV; Are New Pharmacopoeia Standards At Play?
In an effort to increase its footprint in the Chinese vaccine market, GlaxoSmithKline PLC will acquire the remaining 51% equity stake in its joint venture with China's Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. for $39 million in cash, the companies announced June 14
GSK Buys Out Partner Neptunus' Stake in Chinese Vaccines Joint Venture
New Chinese Pharmacopoeia standards that mean increased development spending and longer timelines to launch may be at play.